Pioneering veterinary diagnostics company MI:RNA, headquartered in Edinburgh, has recruited leading veterinary experts to support the advancement of its cutting-edge diagnostic technology. Forming part of MI:RNA’s first clinical advisory board (CAB), they will play a vital role in sharing expertise, fostering curiosity and critical connections, and helping shape key projects. This will include the launch of the company’s first early diagnosis product for Hypertrophic Cardiomyopathy (HCM), one of the most common heart diseases in cats.
